Sagar Lonial, MD, FACP - Innovative Therapeutic Concepts for ASCT-Eligible Patients With Myeloma: Advancing Toward More Effective Care Across Treatment Settings

Go online to PeerView.com/QAJ860 to view the entire program with slides. In this activity, based on a recent live symposium held at the 2019 Transplantation and Cellular Therapy Meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR), experts in myeloma offer guidance on the selection and sequencing of innovative therapies for the ASCT-eligible patients with multiple myeloma, and address several ongoing clinical questions from the choice of novel induction and maintenance options to minimal residual disease monitoring and the use of newer therapeutic platforms for post-transplant relapsed disease. Upon completion of this activity, participants should be better able to: Summarize evidence regarding the safety, efficacy, and current clinical role of emerging and established regimens in conjunction with autologous stem cell transplantation (ASCT) in the management of multiple myeloma, Develop personalized induction and post-ASCT maintenance/consolidation regimens with novel components for eligible patients with multiple myeloma, Select novel therapeutics for the management of relapsed multiple myeloma post-ASCT.